The Effect of Inhibitory Antibodies on Acute Treatment of Bleeding Episodes with OBI-1, an Antihemophilic Factor VIII (recombinant), Porcine Sequence, in Patients with Acquired Hemophilia A

被引：0
|
作者：
Farin, Heinrich D. [1 ]
Novack, Aaron [1 ]
Mo, Min [1 ]
Bourgeois, Christelle [2 ]
Horling, Frank M. [2 ]
Ewenstein, Bruce M. [1 ]
机构：
[1] Baxter Healthcare Corp, Westlake Village, CA USA
[2] Baxter BioSci, Vienna, Austria
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Porcine recombinant factor VIII (Obizur; OBI-1; BAX801): product characteristics and preclinical profile
    Lillicrap, D.
    Schiviz, A.
    Apostol, C.
    Wojciechowski, P.
    Horling, F.
    Lai, C. K.
    Piskernik, C.
    Hoellriegl, W.
    Lollar, P.
    HAEMOPHILIA, 2016, 22 (02) : 308 - 317
  • [22] Efficacy and safety of recombinant porcine factor VIII in Japanese patients with acquired hemophilia A
    Seki, Yoshinobu
    Ogawa, Yoshiyuki
    Kikuchi, Takahide
    Sakaida, Emiko
    Mizuta, Yuki
    Kitagawa, Tadayuki
    Takemura, Kazuhiko
    Miyaguchi, Yasuo
    Nogami, Keiji
    Matsushita, Tadashi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2024, 120 (04) : 482 - 491
  • [23] Real-world use of recombinant porcine sequence factor VIII in the treatment of acquired hemophilia A: EU PASS
    Miesbach, Wolfgang
    Curry, Nicola
    Knoebl, Paul
    Percy, Charles
    Santoro, Rita
    Schmaier, Alvin H.
    Trautmann-Grill, Karolin
    Badejo, Kayode
    Chen, Jie
    Nouri, Masoud
    Oberai, Pooja
    Klamroth, Robert
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2024, 15
  • [24] USE OF PORCINE FACTOR-VIII IN THE TREATMENT OF PATIENTS WITH ACQUIRED HEMOPHILIA
    MORRISON, AE
    LUDLAM, CA
    KESSLER, C
    BLOOD, 1993, 81 (06) : 1513 - 1520
  • [25] Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia A
    Pipe, Steven
    BIOLOGICS-TARGETS & THERAPY, 2009, 3 : 117 - 125
  • [26] Evaluating the financial impact of utilizing recombinant porcine factor VIII or recombinant FVIIa for patients with acquired hemophilia A
    Bullano, Michael
    Cool, Christina
    Schultz, Bob G.
    Durgapal, Sneha
    Sacks, Naomi
    Liu, Yanmei
    Kee, Rebecca
    Batt, Katharine
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2023, 23 (02) : 225 - 230
  • [27] A phase II open-label study evaluating the hemostatic activity, pharmacokinetics and safety of recombinant porcine factor VIII (OBI-1) in hemophilia A patients with inhibitors directed against human FVIII
    Mahlangu, J.
    Andreeva, T.
    Macfarlane, D.
    Reding, M.
    Walsh, C.
    Ewing, N.
    Kessler, M.
    Kempton, C.
    Mathew, P.
    Plyushch, O.
    Shapiro, A.
    St-Louis, J.
    Warrier, I.
    Hoots, K.
    HAEMOPHILIA, 2008, 14 : 15 - 16
  • [28] Recombinant porcine factor VIII in acquired hemophilia A: Experience from two patients and literature review
    Hayden, Alexander
    Candelario, Nellowe
    Moyer, Genevieve
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2022, 6 (02)
  • [29] A phase II open-label study evaluating hemostatic activity, pharmacokinetics and safety of recombinant porcine factor VIII (OBI-1) in hemophilia A patients with alloantibody inhibitors directed against human FVIII
    Mahlangu, Johnny
    Andreeva, Tatiana A.
    Macfarlane, Donald
    Reding, Mark T.
    Walsh, Christopher
    Ritchie, Bruce
    Ewing, Nadia
    Kessler, Craig M.
    Kempton, Christine
    Libby, Edward
    Zozulya, Nadezda
    Shapiro, Amy D.
    St-Louis, Jean
    Warrier, Indira
    Hoots, W. Keith
    Gruppo, Ralph A.
    Mueksch, Josef N.
    BLOOD, 2007, 110 (11) : 241A - 241A
  • [30] Pattern of bleeding episodes in young hemophilia A patients: A natural history of recombinant factor VIII (rFVIII) treatment of previously untreated patients (PUPs).
    Arkin, S
    Lusher, J
    Abildgaard, C
    Bogdanoff, D
    Hurst, D
    BLOOD, 1995, 86 (10) : 3444 - 3444
12345